Open an account

Fibrobiologics

FBLG · NASDAQ

$0.9199−$0.0199 (−2.12%)TodayMarket closed ·
Prev close $0.9398

About FBLG

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 15 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

Employees
15
Headquarters
Houston, Texas
Listed
Jan 31, 2024
Sector
Health Care
Industry
Biotechnology
Website
fibrobiologics.com

FBLG key statistics

Market cap
6.12M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
134.98K
Volume
26
Open price
$0.93
High today
$0.9709
Low today
$0.8812
52 Week high
$9.60
52 Week low
$0.6201

Fibrobiologics (FBLG) at a glance

Fibrobiologics (FBLG) last traded at $0.9199, with a market cap of 6.12M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.8812 and $0.9709. The current price is 4.4% above the day's low and 5.3% below its high.

Volume so far is 26 shares, below the average of 134.98K shares a day.

Over the past year Fibrobiologics has ranged from $0.6201 to $9.60, and now sits 3% of the way up that range.

Fibrobiologics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.66 per share against an estimate of -$0.7344.

The average analyst price target is $6.12, 565.3% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

33%of 3 analyst ratings say Buy
  • Buy33.3%
  • Hold66.7%
  • Sell0.0%
Price target · 3 analystsAvg $6.12
Low
$6.06
Now
$0.9199
High
$6.30

FBLG earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 41.8% on average.

  1. Q3 FY24: reported -$0.20 per share against an estimate of -$1.77
  2. Q4 FY24: reported -$1.80 per share against an estimate of -$1.84
  3. Q1 FY25: reported -$2.80 per share against an estimate of -$2.24
  4. Q2 FY25: reported -$2.40 per share against an estimate of -$2.30
  5. Q3 FY25: reported -$2.60 per share against an estimate of -$2.19
  6. Q4 FY25: reported -$0.60 per share against an estimate of -$1.78
  7. Q1 FY26: reported -$1.33 per share against an estimate of -$1.33
  8. Q2 FY26: reported -$0.66 per share against an estimate of -$0.7344

FBLG news

  • Press releasePRNewswire

    FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting

  • Press releasePRNewswire

    FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

  • Press releasePRNewswire

    FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body

  • Vandana Singh

    EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections

  • Press releasePRNewswire

    FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

  • Press releasePRNewswire

    FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

  • Press releasePRNewswire

    FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

  • Press releasePRNewswire

    FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

Similar companies

Companies in the same industry as Fibrobiologics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.